Ralph Charlton
Chief Tech/Sci/R&D Officer chez SPRUCE BIOSCIENCES, INC.
Fortune : 43 523 $ au 31/03/2024
Profil
Ralph William Charlton is currently the Chief Medical Officer at Spruce Biosciences, Inc. Prior to this, he worked as the Executive Medical Director at Allergan, Inc. from 2018 to 2019, Senior Medical Director-Clinical Development at Ascendis Pharma, Inc. from 2019 to 2020, and Vice President-Clinical Development at 89bio, Inc. from 2020 to 2022.
Charlton earned a doctorate degree from the University of Southern California.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
SPRUCE BIOSCIENCES, INC.
0,13% | 25/03/2024 | 55 373 ( 0,13% ) | 43 523 $ | 31/03/2024 |
Postes actifs de Ralph Charlton
Sociétés | Poste | Début |
---|---|---|
SPRUCE BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 14/03/2022 |
Anciens postes connus de Ralph Charlton
Sociétés | Poste | Fin |
---|---|---|
89BIO, INC. | Chief Tech/Sci/R&D Officer | 01/02/2022 |
Ascendis Pharma, Inc. | Chief Tech/Sci/R&D Officer | 01/11/2020 |
ALLERGAN, INC. | Chief Tech/Sci/R&D Officer | 01/05/2019 |
Formation de Ralph Charlton
University of Southern California | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
SPRUCE BIOSCIENCES, INC. | Health Technology |
89BIO, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Allergan, Inc.
Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Ascendis Pharma, Inc. |